

10/616,579

Connecting via Winsock to STN

Welcome to STN International! Enter x:

Welcome to STN International! Enter x:

Welcome to STN International! Enter x:

Sorry. Your logon could not be completed because
no recognized response was received from the gateway system.
Please check the gateway "Prompt Characters strings".

Welcome to STN International! Enter x:x

LOGINID:sssptal203mxm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****



***** STN Columbus *****

FILE 'HOME' ENTERED AT 14:41:04 ON 09 MAR 2005

=> file reg

=>

Uploading C:\Program Files\Stnexp\Queries\10616579.str



chain nodes :

11 12 13 14 15 18 19

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

2-11 11-12 11-18 12-13 12-14 14-15 14-19

10/616,579

ring bonds :

1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10

exact/norm bonds :

2-11 11-12 11-18 12-13 12-14 14-15 14-19

normalized bonds :

1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10

isolated ring systems :

containing 1 :

G1:O,S

G2:H,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom


11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 18:CLASS 19:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S

G2 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

L3 325 SEA SSS FUL L1

=> file ca

=> s l3

10/616,579

L4 15 L3

=> d ibib abs fhitstr 1-15

10/616,579



L4 ANSWER 1 OF 15 CA COPYRIGHT 2005 ACS on STM
 ACCESSION NUMBER: 141:174087 CA
 TITLE: Preparation of fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1)
 INVENTOR(S): Lee, Chih-Hung; Bayburt, Erol K.; Didomenico, Stanley; Drizin, Irene; Gontsyan, Arthur R.; Koenig, John R.; Perner, Richard J.; Schmidt, Robert G.; Turner, Sean C.; White, Tammie K.; Zheng, Guo Zhu
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 93 pp., Cont.-in-part of U.S. Ser. No. 364,210.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004157849	A1	20040812	US 2003-634678	20030805
US 2003158198	A1	20030821	US 2003-364210	20030211
WO 2005016890	A1	20050224	WO 2004-US25109	20040804

W: AE, AG, AL, AM, AU, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


PRIORITY APPLM. INFO.:
 US 2003-364210 A2 20030211
 US 2002-358220P P 20020220
 US 2003-634678 A 20030805

OTHER SOURCE(S): MARPAT 141:174087
 GI




AB Comps. of formula I (X1-X5 = (substituted) N, (substituted) CH; Z1 = O, NH, S; Z2 = bond, NH, O; L = alkylene, cycloalkylene, piperazinediyl, etc.; R5-R9 = H, alkyl, alkenyl, alkoxy, carboxy, cycloalkyl, formyl,

L4 ANSWER 2 OF 15 CA COPYRIGHT 2005 ACS on STM
 ACCESSION NUMBER: 141:157010 CA
 TITLE: N-Isoquinolin-5-yl-N'-aralkyl-urea and -amide antagonists of human vanilloid receptor 1
 AUTHOR(S): Jetter, Michele C.; Youngman, Mark A.; McNally, James J.; Zhang, Sui-Po; Dubin, Adrienne E.; Nasser, Nadia; Dax, Scott L.
 CORPORATE SOURCE: Johnson & Johnson Pharmaceutical Research and Development, Spring House, PA, 19477, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(12), 3053-3056
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:157010
 AB Starting from a low micromolar agonist lead identified by high-throughput screening, series of N-isquinolin-5-yl-N'-aralkyl ureas and analogous amides were developed as potent antagonists of human vanilloid receptor 1 (VR1). The synthesis and structure-activity relationships (SAR) of the series are described.
 IT 581809-67-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of n-isquinolin-5-yl-N'-aralkyl-urea and -amide including their structure-activity relationships as antagonists of human vanilloid receptor 1)
 RN 581809-67-8 CA
 CN Urea, N-5-isquinolinyl-N'-[4-(trifluoromethyl)phenyl]methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 1 OF 15 CA COPYRIGHT 2005 ACS on STM (Continued)
 ACCESSION NUMBER: 141:174087 CA
 TITLE: Preparation of fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity. Thus, II was prepd. from 5-aminoisoquinoline and 2-(3-fluorophenyl)ethylamine. The prepd. compds. were found to be antagonists of VR1 with IC50 of 0.1 nM to 1000 nM.
 IT 581809-65-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of fused azabicyclic compds. as vanilloid receptor 1 inhibitors)
 RN 581809-65-6 CA
 CN Urea, N-[2-(3-fluorophenyl)ethyl]-N'-5-isquinolinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 15 CA COPYRIGHT 2005 ACS on STM
 ACCESSION NUMBER: 141:46759 CA
 TITLE: Design and synthesis of Rho kinase inhibitors (I)
 AUTHOR(S): Takami, Atsuya; Iwakubo, Masayuki; Okada, Yuji; Kawata, Takehisa; Odai, Hideharu; Takahashi, Nobuaki; Shindo, Kazutoshi; Kimura, Kaname; Tagami, Yoshimichi; Miyake, Mika; Fukushima, Kayoko; Inagaki, Masaki; Amano, Mutsuki; Kaibuchi, Kozor; Iijima, Hiroshi
 CORPORATE SOURCE: Pharmaceutical Research Laboratories, Kirin Brewery Co. Ltd., Gunma, Takasaki-shi, 370-1295, Japan
 SOURCE: Bioorganic & Medicinal Chemistry (2004), 12(9), 2115-2137
 CODEN: BMECEP; ISSN: 0968-0896
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:46759
 AB Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homol. model of Rho kinase. A docking simulation using the ligand-binding pocket of the Rho kinase model helped to comprehensively understand and to predict the structure-activity relationship of the inhibitors. This understanding was useful for developing new Rho kinase inhibitors of higher potency and selectivity. We identified several potent platforms for developing the Rho kinase inhibitors, namely, pyridine, 1H-indazole, isoquinoline, and phthalimide.
 IT 709046-05-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (design and synthesis of Rho kinase inhibitors)
 RN 709046-05-9 CA
 CN Urea, N-[(2,6-difluorophenyl)methyl]-N'-5-isquinolinyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/616,579

L4 ANSWER 4 OF 15 CA COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 140:111290 CA
 TITLE: Preparation of naphthalenylureas, quinolinylureas, and isoquinolinylureas as modulators of vanilloid VR1 receptor ligands.
 INVENTOR(S): Codd, Ellen; Dax, Scott L.; Jetter, Michele; McDonnell, Mark; McNally, James J.; Youngman, Mark
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 205 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007459	A2	20040122	WO 2003-US21518	20030710
WO 2004007459	A3	20040378		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2004157865 A1 20040812 US 2003-616579 20030710
 PRIORITY APPL. INFO.: US 2002-395728P P 20020712
 US 2002-395951P P 20020715
 OTHER SOURCE(S): MARPAT 140:111290
 GI




AB Title compds. [I; R1, R2 = H, OH, halo, (substituted) alkyl, alkoxy, alkylthio, cycloalkyl, cycloalkoxy, etc.; R3 = H, OH, F, Cl, NO2, amino; R4 = (substituted) alkylene; R5 = H, alkyl; R6 = (substituted) Ph, naphthyl, heteroaryl, cycloalkyl, heterocyclyl; X = CH, N, NO; Y = C, N; Z = O, S], were prepared as potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain. Thus, (1-chloroisoquinolin-5-yl)carbamate Ph ester and 4-trifluoromethylbenzylamine were stirred overnight in DMSO to give 61%

L4 ANSWER 5 OF 15 CA COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 139:292162 CA
 TITLE: Heteroaromatic ureas as vanilloid receptor (VR1) modulators, in particular antagonists, for treating pain and/or inflammation
 INVENTOR(S): Brown, Rebecca Elizabeth; Doughty, Victoria Alexandras; Hollingsworth, Gregory John; Jones, A. Brian; Lindon, Matthew John; Moyes, Christopher Richard; Rogers, Lauren
 PATENT ASSIGNEE(S): Merck Sharp & Dohme Limited, UK
 SOURCE: PCT Int. Appl., 110 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080578	A1	20031002	WO 2003-GB1302	20030321

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2479150 AA 20031002 CA 2003-2479150 20030321
 EP 1490340 A1 20041229 EP 2003-710014 20030321
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 PRIORITY APPL. INFO.: GB 2002-6876 A 20020322
 WO 2003-GB1302 W 20030321
 OTHER SOURCE(S): MARPAT 139:292162
 GI




AB Title compds. I [wherein A, B, D, E are each C or N with the proviso that one or more are N; R1, R2 = independently H, halo, alk(enyl/ynyl), haloalkyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, NH2 and derivs., CO2H and derivs., (un)substituted alkyl, alkoxy; R3, R4 = independently H, alk(en/yn)yl; R5, R6 = at each occurrence, independently H, alk(enyl/ynyl), alkoxy, acyloxy, carbony and derivs., CONH2 and derivs., sulfonyl(alkyl/amino), aryl, hetero(aryl/cyclyl), (un)substituted alkyl, or CR5R6 = 3-6 carbocyclic membered ring; R7, R8 = at each occurrence, independently H, alk(en/yn)yl, cycloalkyl, fluoroalkyl, or NR7R8 =

L4 ANSWER 4 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)
 1-(1-chloroisoquinolin-5-yl)-3-(4-trifluoromethylbenzyl)urea. I bound to VR1 receptors with Ki = 0.10-100,000 nM.
 IT 581809-67-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of naphthalenylureas, quinolinylureas, and isoquinolinylureas as modulators of vanilloid VR1 receptor ligands)
 RN 581809-67-8 CA
 CN Urea, N-5-isoquinolinyl-N'-[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)
 (un)substituted 4-7 heteroaliph. membered ring; X = O, S or -N(CN); Y = aryl, heteroaryl, carbocyclyl, fused carbocyclyl group; n = 0, 1, 2, 3; and their pharmaceutically acceptable salts, N-oxides, and prodrugs were prep'd. as vanilloid receptor (VR1) modulators, in particular antagonists, for treating conditions or diseases in which pain and/or inflammation predominates. For example, 1-isoquinolin-5-yl-3-(3-phenylpropyl)urea was prep'd. by reacting isoquinoline-5-carboxylic acid with diphenylphosphoryl azide in toluene at reflux for 1 h through a Curtius rearrangement, followed by addn. of 3-phenylpropylamine and reflux for 18 h. I bound to the VR1 receptor with an IC50 < 1 μM, and in the majority of cases, < 200 nM. I are predominantly VR1 antagonists with a few of them VR1 partial antagonists and VR1 partial agonists. Thus, I and their pharmaceutical compns. are useful for treating pain and/or inflammation.
 IT 581809-67-8P, 1-isoquinolin-5-yl-3-[4-(trifluoromethyl)benzyl]urea
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (VR1 receptor ligand; preparation of heteroarom. ureas as vanilloid receptor modulators for treating pain and inflammation)
 RN 581809-67-8 CA
 CN Urea, N-5-isoquinolinyl-N'-[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LA ANSWER 6 OF 15 CA COPYRIGHT 2005 ACS ON STN
 ACCESSION NUMBER: 1391:197383 CA
 TITLE: Preparation of fused azabicyclic compounds that
 inhibit vanilloid receptor subtype 1 (VR1)
 INVENTOR(S): Lee, Chih-Hung; Bayburt, Erol K.; Didomenico, Stanley;
 Drizina, Irene; Gomsyan, Arthur R.; Koenig, John R.;
 Berner, Richard J.; Schmidt, Robert G.; Turner, Sean
 C.; White, Tammie K.; Zheng, Guo Zhu
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 79 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003158198	A1	20030821	US 2003-364210	20030211
CA 2476936	AA	20030828	CA 2003-2476936	20030211
WO 2003070247	AA	20030828	WO 2003-US4187	20030211
<p>W: CA, JP, MX RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR</p>				
EP 1478363	AA	20041124	EP 2003-716014	20030211
<p>R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, BE, HU, SK</p>				
US 2004157849	A1	20040812	US 2003-634678	20030805
US 2004299884	A1	20041021	US 2004-842311	20040510
<p>PRIORITY APPL. INFO.:</p> <p>US 2002-35820P P 20020220</p> <p>US 2002-364210 A 20020220</p> <p>US 2003-364210 A 20030211</p> <p>WO 2003-US4187 W 20030211</p>				


OTHER SOURCE(S): MARPAT 139:197383
GI



AB Compds. of formula I [X1-X5 = (substituted) N, (substituted) CH; Z1 = O, NH, S; Z2 = bond, NH, O, =, -alkylene, cycloalkylene, piperazinediyl, etc.; R5-R9 = H, alkyl, alkenyl, alkoxy, carboxy, cycloalkyl, formyl, mercapto, etc.; R10 = H, aryl, cycloalkyl, heterocyclyl] are prepared as vanilloid receptor subtype 1 (VR1) antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder


LA ANSWER 7 OF 15 CA COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 139197382 CA
 TITLE: Preparation of isoquinolines, indoles, and related
 compounds as antagonists of vanilloid receptor subtype
 1 (VR1).
 INVENTOR(S): Lee, Chih-Hung; Bayburt, Erol K.; Didomenico, Stanley;
 Drizin, Irene; Gomsyan, Arthur R.; Koenig, John R.;
 Ferner, Richard J.; Schmidt, Robert G.; Turner, Sean
 C.; White, Tammie K.; Zheng, Guo Zhu
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 38 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KLIN	DATE	APPLICATION NO.	DATE
US 2003158188	AI	20030821	US 2002-79324	20020220
CA 2476936	AI	20030828	CA 2003-2476936	20030221
WO 2003072047	AI	20030828	WO 2003-US4187	20030211
W: CA, JP, MX RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, SE, SI, SK, TR EP 1478363 20041124 EP 2003-716014 20030211 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-79324	A 20020220
			US 2003-364210	A 20030211
			WO 2003-US4187	W 20030211
OTHER SOURCE(S):		MARPAT 139:197382		
GI				




AB Title compounds: [(1) X-1 - N, Crl; X-2 - N, Crl; X-3 - N, NR3, CR3; X-4 - null.
N, CR4; X-5 - N, CH2; Z1 - O, NH, S, Z2 - NH, O; L - piperazinylkene,
alkenylene, alkylene, alkenylene, cycloalkylene, (CH2)n SO (CH2)n, NH2, NHNH,
n = 1-6; R1, CR3, RS, RE, R7 - H, alkenyl, alkonyl, alkoxycarbonyl,
alkoxyalkyl, arylalkyl, arylalkoxy, arylalkoxy, COOAr, COOR,
alkynyl, COZH, ACOZHe, cyano, cyanocalkyl, cycloalkyl, cycloalkoxyalkyl,
ethylenedioxy, CHO, ACHO, haloalkoxy, haloalkyl, haloalkylthio, halo, OH,
HOA, methylethylenedioxy, SH, ASH, NO2, (CF3)2(HO)C, NRASO2R, SO2ORA, SO2RB,
NRASO2R, NRASO2R, NRASO2R, NRASO2R, NRASO2R, NRASO2R, NRASO2R, NRASO2R,
CHO, aryl, alkenyl; R2, R4 - H, alkenyl, AO, alkoxycarbonyl, AOA, AO2C,

L4	ANSWER 6 OF 1 CA COPYRIGHT 2005 ACS ON 5-NN (Continued) overactivity. Thus, II was prepd. from 8-aminoisouquinoline and 2-(3-fluorophenyl)ethylamine. The prepd. compds. were found to be antagonists of VRL with IC50 of 1 nM to 1000 nM.
IT	581809-65-6P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of fused azabicyclic compds. as vanilloid receptor 1 inhibitors)
RN	581809-65-6 CA
CN	Urea, N-[2-(3-fluorophenyl)ethyl]-N'-5-isouquinoliny- (9CI) (CA INDEX NAME)





L4 ANSWER 7 OF 15 CA COPYRIGHT 2005 ACS ON STN (Continued)
 AOC2CA, A, ACO, ACOA, ACO2, AS, alkynyl, CO2H, carboxalkyl, cyano,
 cyanoalkyl, cycloalkyl, cycloalkylalkyl, ethylenedioxy, CHO, ACHO,
 haloalkoxy, haloalkyl, haloalkylalkyl, halo, HO, HOA, methylenedioxy, SH,
 HSA, NO2, (CF3)2(HO)C, NRAS(O)2RB, SO2ORA, SO2RB, (NZABZ) (NZABZ)alkyl,
 (NZABZ)ACO, (NZABZ)CO, (NZABZ)COA, (NZABZ)SO2, (NZABZ)C:(NH),
 (NZABZ)C:(NC)NH, (NZABZ)C:(NH)NH RA = H, AR RB = A, aryl, aralkyl; R8 =
 H, R8 = H, AR RB = A, aryl, aralkyl; A alkyl, A alkyl = optional
 double bond), were prep'd for treating pain, inflammatory thermal
 hyperalgesia, urinary incontinence and bladder overactivity (no data).
 Thus, 2,2,2-trichloro-N-5-isoquinolin-5-ylacetamide, (prepn. given) DBU, and
 2-(3-fluorophenyl)ethylamine in acetonitrile were refluxed for 10 h to
 give 65% N-[2-(3-fluorophenyl)ethyl]-N'-isoquinolin-5-ylurea.
 IT 581810-09-5F
 P (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BTL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (claimed compound; preparation of isoquinolines, indoles, and related
 compds.
 as antagonists of vanilloid receptor subtype 1)
 RN 581810-09-5 CA
 CN N-[3-(5-dimethylphenyl)methyl]-N'-5-isoquinolinyl- (9CI) (CA INDEX
 NAME)




L4 ANSWER 8 OF 15 CA COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 139:85361 CA
 TITLE: Preparation of ureas as vanilloid receptor (VR1) antagonists
 INVENTOR(S): Rami, Marhad Kantilal; Thompson, Mervyn
 PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053945	A2	20030703	WO 2002-GB5812	20021219
WO 2003053945	A3	20040311		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
EP 1474403	A2	20041110	EP 2002-788192	20021219
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
PRIORITY APPLN. INFO.:			GB 2001-30550	A 20011220
			WO 2002-GB5812	W 20021219
OTHER SOURCE(S):			MARPAT 139:85361	
GI				




L4 ANSWER 9 OF 15 CA COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 139:79144 CA
 TITLE: Preparation of 5-member cyclic compounds as antiinflammatory agents
 INVENTOR(S): Fujiwara, Norio; Fujita, Kazushi; Yasutoku, Fujio; Kanzawa, Toshishige; Kawakami, Hajime
 PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 72 pp.
 CODEN: JKKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003192591	A2	20030709	JP 2001-396157	20011227
PRIORITY APPLN. INFO.:			JP 2001-396157	20011227
OTHER SOURCE(S):			MARPAT 139:79144	
GI				




AB The title compds. (I; X = O, S; R1 = H, (substituted)alkyl, etc.; R2 = (substituted)alkyl or aryl; Y1 = alkylene, etc.; R3 = (substituted)aryl; Y2 = (substituted)alkylene; R4 = alkyl, etc.; R5 = H, etc.) and their salts are claimed as antiinflammatory agents antiallergics by inhibiting leukocyte infiltration and are useful for treatment of autoimmune diseases. I and their salts were prepared
 IT 553684-63-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 5-member cyclic compds. as antiinflammatory agents)
 RN 553684-63-2 CA
 CN Carbamate acid, [3-[[[(5-isoquinolinylamino)thioxomethyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)

AB The title compds. (I; P = Ph, naphthyl, heterocyclyl; R1 = H, halo, alkyl, etc.; R2 = II; X = a bond, C, O, NR8; R3 = H, halo, alkyl, etc.; R4 = H, alkyl; R8 = H, alkyl, aryl; n = 2-6; p = 0-4; q = 0-3; r = 0-2), useful for treating disorders or diseases in which an antagonist of the vanilloid receptor (VR1) is beneficial, were prepared Thus, reacting 2-(7-fluoro-2,3-dihydrobenzo[1,4]oxazin-4-yl)ethylamine (preparation given) with 2-bromophenyl isocyanate in CH2Cl2 afforded 96% III which had a pKb > 7.0 in test for vanilloid receptor (VR1) antagonist activity.
 IT 552866-91-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of ureas as vanilloid receptor (VR1) antagonists)
 RN 552866-91-8 CA
 CN Urea, N-[2-(7-fluoro-2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethyl]-N'-(1-methyl-5-isoquinolinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 15 CA COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 123:198626 CA
 TITLE: Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
 INVENTOR(S): Chang, George; Hamanaka, Ernest S.; McCarthy, Peter A.; Truong, Thien; Walker, Frederick J.
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: U.S., 36 pp. Cont.-in-part of U.S. Ser. No. 648,677, abandoned
 CODEN: USKKAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5362878	A	19941108	US 1992-916651	19920720
ES 2076865	B1	19960801	ES 1993-1508	19930705
ES 2076865	A1	19951101		
US 5656634	A	19970812	US 1994-251075	19940531
PRIORITY APPLN. INFO.:			US 1991-648677	B2 19910321
			US 1992-916651	19920720
OTHER SOURCE(S):			MARPAT 123:198626	
GI				




AB Compds. of the formula I wherein R21 is C1-3-alkyl and R22 is H or C1-3-alkyl which are intermediates useful in the preparation of compds. of the formula R1NHCOQ (II) and the pharmaceutically acceptable salts thereof, wherein Q and R1 are as defined in the specification. The compds. of formula II are inhibitors of acyl CoA: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents (no data). Pharmaceutical formulations were given.
 IT 134989-87-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (intermediates for making N-aryl and N-heteroarylamide and urea derivs. as inhibitors of acyl CoA: cholesterol acyl transferase)
 RN 134989-87-0 CA
 CN Urea, N-heptyl-N'-5-isoquinolinyl-N-[[4-(3-methylbutyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

10/616,579

L4 ANSWER 10 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)




L4 ANSWER 11 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)
 3-bromo-8-(2,6-dichloro-3-nitrobenzyloxy)-2-methylimidazo[1,2-a]pyridine.
 I at 10-5 M gave 95-100% inhibition of 3H-bradykinin binding to guinea pig ileum preps.
 IT 160645-13-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as bradykinin antagonist)
 RN 160645-13-6 CA
 CN Acetamide, N-[3-[(3-bromo-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]methyl]-2,4-dichlorophenyl]-2-[(5-isoquinolinylamino)carbonyl]amino]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 15 CA COPYRIGHT 2005 ACS on STN
 122:105879 CA
 ACCESSION NUMBER:
 TITLE: Preparation of imidazo[1,2-a]pyridines as bradykinin antagonists.
 INVENTOR(S): Oku, Teruo; Kayakiri, Hiroshi; Satoh, Shigeki; Abe, Yoshito; Yuki, Sawada; Tanaka, Hirokazu
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 117 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 596406	A1	19940511	EP 1993-117474	19931028
EP 596406	B1	19981216		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9350242	A1	19940512	AU 1993-50242	19931026
AU 686115	B2	19980205		
ZA 9308011	A	19940609	ZA 1993-8011	19931027
IL 107426	A1	19970713	IL 1993-107426	19931027
AT 174596	E	19990115	AT 1993-117474	19931028
ES 2125294	T3	19990301	ES 1993-117474	19931028
CA 2102137	AA	19940503	CA 1993-2102137	19931101
CN 1089947	A	19940727	CN 1993-119684	19931101
HU 66302	A2	19941128	HU 1993-3119	19931102
JP 07300478	A2	19951114	JP 1993-274643	19931102
JP 2763036	B2	19980611		
US 5574042	A	19961112	US 1995-441786	19950516
US 5750699	A	19980512	US 1996-662198	19960612
PRIORITY APPLN. INFO.:			GB 1992-22947	A 19921102
			GB 1993-4249	A 19930303
			US 1993-142967	B2 19931029
			US 1994-235632	B1 19940429
			US 1995-441786	A3 19950516

OTHER SOURCE(S): MARPAT 122:105879
 GI




AB Title compds. [I: R1 = halo; R2, R3 = H, alkyl, haloalkyl, acyl, R4 = aryl having suitable substituent(s), heterocyclyl optionally having suitable substituent(s); Q = O or NR11; R11 = H, acyl; and A = alkylene], were prepared. Thus, 8-(2,6-dichloro-3-nitrobenzyloxy)-2-methylimidazo[1,2-a]pyridine was stirred with N-bromosuccinimide in EtOH/dioxane to give

L4 ANSWER 12 OF 15 CA COPYRIGHT 2005 ACS on STN
 116:194114 CA
 ACCESSION NUMBER:
 TITLE: Antiparasitic agents. Part XV. Synthesis of 2-substituted 1(3)H-imidazo[4,5-f]isoquinolines as anthelmintic agents
 AUTHOR(S): Kumar, Pramod; Agarwal, Shiv K.; Bhakuni, D. S.
 CORPORATE SOURCE: Div. Med. Chem., Cent. Drug Res. Inst., Lucknow, 226 001, India
 SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1992), 31B(3), 177-82
 CODEN: IJCSDB; ISSN: 0376-4699
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB 5-(2,4-Dioxo-1H-quinazolin-3-yl)isoquinoline (I) and 2-(methyl-/carbomethoxyamino-/furyl-/trifluoromethyl)-1(3)H-imidazo[4,5-f]isoquinolines, e.g. II, were synthesized and tested for their anthelmintic and antifilarial activities against Ancylostoma ceylanicum, Nippostrongylus brasiliensis, Hymenolepis nana, and Litomosoides carinii. Thus, 5-acetamidoisoquinoline was nitrated followed by reduction to give 5-acetamido-6-aminoisoquinoline, which was cyclized by HCl to give II.

IT 140192-80-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 140192-80-9 CA
 CN Thiourea, N-ethyl-N'-5-isoquinolinyl- (9CI) (CA INDEX NAME)



10/616,579

L4 ANSWER 13 OF 15 CA COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 115:71632 CA
 TITLE: Preparation of new N-aryl and N-heteroaryl amide and urea derivatives as inhibitors of acyl coenzyme A:cholesterol acyltransferase
 INVENTOR(S): McCarthy, Peter A.; Walker, Frederick J.; Truong, Thien; Hamanaka, Ernest S.; Chang, George
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: Eur. Pat. Appl., 85 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 418071	A2	19910320	EP 1990-310009	19900913
EP 418071	A3	19920325		
EP 418071	B1	19950426		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
WO 9104027	A1	19910404	WO 1989-US4033	19890915
W: FI, HU, NO, RO, SU, US				
IL 95610	A1	19941229	IL 1990-95610	19900907
DD 298092	A5	19920206	DD 1990-343971	19900912
CA 2025301	AA	19910316	CA 1990-2025301	19900913
CA 2025301	C	20011016		
EP 609960	A1	19940810	EP 1994-200437	19900913
EP 609960	B1	19990303		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 121730	E	19950515	AT 1990-310009	19900913
ES 2071033	T3	19950616	ES 1990-310009	19900913
AT 177082	E	19990315	AT 1994-200437	19900913
ES 2127878	T3	19990501	ES 1994-200437	19900913
NO 9004022	A	19910318	NO 1990-4022	19900914
CN 1050183	A	19910327	CN 1990-108294	19900914
HU 54625	A2	19910328	HU 1990-5991	19900914
AU 9062553	A1	19910418	AU 1990-62553	19900914
AU 652345	B2	19940825		
JP 03120243	A2	19910522	JP 1990-245969	19900914
JP 08025974	B4	19960313		
ZA 9007346	A	19920527	ZA 1990-7346	19900914
PL 165370	B1	19941230	PL 1990-286899	19900914
PL 165357	B1	19941230	PL 1990-291470	19900914
HU 70027	A2	19950928	HU 1993-2945	19900914
FI 111362	B1	20030715	FI 1990-4537	19900914
PRIORITY APPLN. INFO.:			WO 1989-US4033	A 19890915
OTHER SOURCE(S):		MARPAT 115:71632	EP 1990-310009	A3 19900913

GI

L4 ANSWER 14 OF 15 CA COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 93:26292 CA
 TITLE: Isoquinoline derivatives
 PATENT ASSIGNEE(S): Rhone-Poulenc Industries S. A., Fr.
 SOURCE: Belg., 33 pp.
 CODEN: BEXXAL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 875797	A1	19791023	BE 1979-194791	19790423
FR 2424270	A1	19791123	FR 1978-12026	19780424
FR 2424270	B1	19800919		
FR 2449087	A2	19800919	FR 1979-4004	19790216
NL 7902993	A	19791026	NL 1979-2993	19790417
AU 7946219	A1	19791101	AU 1979-46219	19790420
GB 2020280	A	19791114	GB 1979-13821	19790420
GB 2020280	B2	19820728		
JP 55007260	A2	19800119	JP 1979-48895	19790420
ZA 7901893	A	19800430	ZA 1979-1893	19790420
DK 7901669	A	19791025	DK 1979-1669	19790423
SE 7903554	A	19791025	SE 1979-3554	19790423
ES 479878	A1	19800816	ES 1979-479878	19790424
ES 482070	A1	19800401	ES 1979-482070	19790629
PRIORITY APPLN. INFO.:			FR 1978-12026	A 19780424
			FR 1979-4004	A 19790216


GI



AB The cyclocondensation reaction of aminoisoquinolines I [Z (in the 4-, 5-, 6-, 7-, or 8-position) = S-alkylisothiourea, NHCS2H alkyl ester, isothiocyanato; R and R1 (same or different) are H, halo, alkyl, alkoxy, alkoxyalkyl, alkylthio, dialkylamino] with H2NCH2CH2NHR2 (R2 = H, hydroxyalkyl) gave the resp. (imidazolinylamino)isoquinolines II, useful as antihypertensives (no data). 4-(Thiourea)isoquinoline was S-methylated, and the isothiourea derivative obtained was heated 7 h with H2NCH2CH2NHR2 in EtOH to give 4-[(4,5-dihydro-2-imidazolyl)amino]isoquinoline.

IT 72677-81-79
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and deacylation of)
 RN 72677-81-7 CA
 CN Benzanide, N-[(5-isoquinolinylamino)thiomethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)




AB Approx. 250 title amides and ureas R1NHCOQ [Q = CR2R3R4, NR5R6; R1 = (substituted) pyridyl, pyrimidinyl, quinolinyl, pyridoimidazolyl, etc., substituted Ph; R2-R4 = H, alkyl, hydrocarbyl, XR7, phenylalkyl, cycloalkyl, or R3R3 forms cycloalkyl, cycloalkenyl, bicycloalkyl, etc.; R5, R6 = alkyl, phenylalkyl, alkylphenylalkyl; R7 = alkyl, cycloalkyl, phenylalkyl, thiazolyl, pyridyl, etc.; X = O, S, SO, SO2, NH, etc.; numerous provisos] were prepared as hypolipidemics and antithrombotics (no data). For example, 2-(hexylthio)decanoic acid was refluxed with SOCl2 in C6H6 to give the acid chloride, which was added to 5-amino-4,6-bis(methylthio)-2-methylpyrimidine in CH2Cl2 followed by refluxing and purification to give 72.4% title amide I.

IT 134989-87-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as hypolipidemic)

RN 134989-87-0 CA
 CN Urea, N-heptyl-N'-5-isoquinolinyl-N-[(4-(3-methylbutyl)phenyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)




10/616,579

L4 ANSWER 15 OF 15 CA COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 92:111013 CA
 TITLE: Isoquinoline derivatives
 INVENTOR(S): Deprez, Dominique; Farge, Daniel; Hucherot, Jean
 PATENT ASSIGNEE(S): Jaques, Moutonnier, Claude
 SOURCE: Rhone-Poulenc Industries S. A., Fr.
 Ger. Offen., 40 pp.
 CODEN: GWXXEX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2916577	A1	19791031	DE 1979-2916577	19790424
FR 2424270	A1	19791123	FR 1978-12026	19780424
FR 2424270	B1	19800919		
FR 2449087	A2	19800912	FR 1979-4004	19790216
NL 7902993	A	19791026	NL 1979-2993	19790417
AU 7946219	A1	19791101	AU 1979-46219	19790420
GB 2020280	A	19791114	GB 1979-13821	19790420
GB 2020280	B2	19820728		
JP 55007260	A2	19800119	JP 1979-48895	19790420
ZA 7901893	A	19800430	ZA 1979-1893	19790420
DK 7901669	A	19791025	DK 1979-1669	19790423
SE 7903554	A	19791025	SE 1979-3554	19790423
ES 479878	A1	19800816	ES 1979-479878	19790424
ES 482070	A1	19800401	ES 1979-482070	19790629
PRIORITY APPLN. INFO.:			FR 1978-12026	A 19780424
			FR 1979-4004	A 19790216

GI




AB The antihypertensive (no data) compds. I R = H, hydroxyalkyl, R₁ and R₂ = H, halogen, alkyl, alkoxy, alkoxyalkyl, alkylthio, dialkylamino) and their salts were prepared. Thus, 5-(2-methylisothioureido)isoquinoline-HI reacted with H₂NCH₂CH₂NH₂ in EtOH to give 4-[(4,5-dihydro-2-imidazolyl)amino]isoquinoline.

IT 72677-81-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREF (Preparation); RACT (Reactant or reagent)
 (preparation and hydrolysis of)

RN 72677-81-7 CA
 CN Benzamide, N-[(5-isoquinolinylamino)thiomethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)



10/616,579

=> file uspatfull

=> s l3

L5 9 L3

=> d ibib abs 1-9

10/616,579

L5 ANSWER 1 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:268341 USPATFULL
TITLE: Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
INVENTOR(S): Lee, Chih-Hung, Vernon Hills, IL, UNITED STATES
Bayburt, Erol K., Gurnee, IL, UNITED STATES
DiDomenico, Stanley, JR., Richmond, IL, UNITED STATES
Drizin, Irene, Wadsworth, IL, UNITED STATES
Gomtsyan, Arthur R., Vernon Hills, IL, UNITED STATES
Koenig, John R., Chicago, IL, UNITED STATES
Perner, Richard J., Gurnee, IL, UNITED STATES
Schmidt, Robert G., JR., Waukegan, IL, UNITED STATES
Turner, Sean C., Evanston, IL, UNITED STATES
White, Tammie K., Gurnee, IL, UNITED STATES
Zheng, Guo Zhu, Lake Bluff, IL, UNITED STATES

NUMBER	KIND	DATE
US 2004209884	A1	20041021
US 2004-842311	A1	20040510 (10)

PATENT INFORMATION: Division of Ser. No. US 2003-364210, filed on 11 Feb 2003, PENDING

NUMBER	DATE
US 2002-358220P	20020220 (60)

PRIORITY INFORMATION: Utility
DOCUMENT TYPE: APPLICATION
FILE SEGMENT: STEVEN F. WEINSTOCK, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
LEGAL REPRESENTATIVE: 84
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 7060
LINE COUNT: 7060
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I) ##STR1##

are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:203957 USPATFULL
TITLE: Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
INVENTOR(S): Lee, Chih-Hung, Vernon Hills, IL, UNITED STATES
Bayburt, Erol K., Gurnee, IL, UNITED STATES
DiDomenico, Stanley, JR., Richmond, IL, UNITED STATES
Drizin, Irene, Wadsworth, IL, UNITED STATES
Gomtsyan, Arthur R., Vernon Hills, IL, UNITED STATES
Koenig, John R., Chicago, IL, UNITED STATES
Perner, Richard J., Gurnee, IL, UNITED STATES
Schmidt, Robert G., JR., Waukegan, IL, UNITED STATES
Turner, Sean C., Evanston, IL, UNITED STATES
White, Tammie K., Gurnee, IL, UNITED STATES
Zheng, Guo Zhu, Lake Bluff, IL, UNITED STATES

NUMBER	KIND	DATE
US 2004157849	A1	20040812
US 2003-634678	A1	20030805 (10)

PATENT INFORMATION: Continuation-in-part of Ser. No. US 2003-364210, filed on 11 Feb 2003, PENDING
APPLICATION INFO.: Utility
RELATED APPLN. INFO.: APPLICATION
DOCUMENT TYPE: STEVEN F. WEINSTOCK, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
LEGAL REPRESENTATIVE: 97
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 8346
LINE COUNT: 8346
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I) ##STR1##

are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:203973 USPATFULL
TITLE: Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor
INVENTOR(S): Codd, Ellen, Blue Bell, PA, UNITED STATES
Dax, Scott L., Landenberg, PA, UNITED STATES
Jetter, Michele, UNITED STATES
McDonnell, Mark, Lansdale, PA, UNITED STATES
McNally, James J., Souderton, PA, UNITED STATES
Youngman, Mark, Warminster, PA, UNITED STATES

NUMBER	KIND	DATE
US 2004157865	A1	20040812
US 2003-616579	A1	20030710 (10)

PATENT INFORMATION: Utility
APPLICATION INFO.: APPLICATION
PRIORITY INFORMATION: PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
DOCUMENT TYPE: 120
FILE SEGMENT: 1
LEGAL REPRESENTATIVE: 7057
NUMBER OF CLAIMS: CAS INDEXING IS AVAILABLE FOR THIS PATENT.
EXEMPLARY CLAIM: AB This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to naphthol, quinoline and isoquinoline-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:226385 USPATFULL
TITLE: Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
INVENTOR(S): Lee, Chih-Hung, Vernon Hills, IL, UNITED STATES
Bayburt, Erol K., Gurnee, IL, UNITED STATES
DiDomenico, Stanley, JR., Richmond, IL, UNITED STATES
Drizin, Irene, Wadsworth, IL, UNITED STATES
Gomtsyan, Arthur R., Vernon Hills, IL, UNITED STATES
Koenig, John R., Chicago, IL, UNITED STATES
Perner, Richard J., Gurnee, IL, UNITED STATES
Schmidt, Robert G., JR., Waukegan, IL, UNITED STATES
Turner, Sean C., Evanston, IL, UNITED STATES
White, Tammie K., Gurnee, IL, UNITED STATES
Zheng, Guo Zhu, Lake Bluff, IL, UNITED STATES

NUMBER	KIND	DATE
US 2003158198	A1	20030821
US 2003-364210	A1	20030211 (10)

PATENT INFORMATION: Utility
APPLICATION INFO.: APPLICATION
PRIORITY INFORMATION: 20020220 (60)
DOCUMENT TYPE: APPLICATION
FILE SEGMENT: STEVEN F. WEINSTOCK, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
LEGAL REPRESENTATIVE: 84
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 7067
LINE COUNT: 7067
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compound of formula (I) ##STR1##

are novel VR1 antagonist that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

10/616,579

L5 ANSWER 5 OF 9 USPATFULL on STN
 ACCESSION NUMBER: 2003:226375 USPATFULL
 TITLE: Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
 INVENTOR(S): Lee, Chih-Hung, Vernon Hills, IL, UNITED STATES
 Bayburt, Erol K., Gurnee, IL, UNITED STATES
 DiDomenico, Stanley, JR., Richmond, IL, UNITED STATES
 Drizin, Irene, Wadsworth, IL, UNITED STATES
 Gontsyan, Arthur R., Vernon Hills, IL, UNITED STATES
 Koenig, John R., Chicago, IL, UNITED STATES
 Perner, Richard J., Gurnee, IL, UNITED STATES
 Schmidt, Robert G., JR., Waukegan, IL, UNITED STATES
 Turner, Sean C., Evanston, IL, UNITED STATES
 White, Tammie K., Gurnee, IL, UNITED STATES
 Zheng, Guo Zhu, Lake Bluff, IL, UNITED STATES

NUMBER	KIND	DATE
US 2003158188	A1	20030821
US 2002-79324	A1	20020220 (10)

PATENT INFORMATION: US 2003158188
 APPLICATION INFO.: US 2002-79324
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: STEVEN F. WEINSTOCK, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
 NUMBER OF CLAIMS: 68
 EXEMPLARY CLAIM: 1
 LINE COUNT: 3296
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 9 USPATFULL on STN
 ACCESSION NUMBER: 1998:51772 USPATFULL
 TITLE: Method of preparing certain 3-halo-imidazopyridines
 INVENTOR(S): Oku, Teruo, Tsukuba, Japan
 Kayakiri, Hiroshi, Tsukuba, Japan
 Satoh, Shigeki, Tsukuba, Japan
 Abe, Yoshito, Ibaraki, Japan
 Sawada, Yuki, Tsukuba, Japan
 Tanaka, Hirokazu, Takarazuka, Japan
 Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan
 (non-U.S. corporation)

NUMBER	KIND	DATE
US 5750699		19980512
US 1996-662198		19960612 (8)

PATENT INFORMATION: Division of Ser. No. US 1995-441786, filed on 16 May 1995, now patented, Pat. No. US 5574042 which is a continuation of Ser. No. US 1994-235632, filed on 29 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-142967, filed on 29 Oct 1993, now abandoned
 RELATED APPLN. INFO.:
 NUMBER DATE
 PRIORITY INFORMATION: GB 1992-22947 19921102
 GB 1993-4249 19930303
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Dentz, Bernard
 LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
 NUMBER OF CLAIMS: 1
 EXEMPLARY CLAIM: 1
 LINE COUNT: 7725
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to bradykinin antagonists of the formula: ##STR1## wherein R.sup.1 is halogen,
 R.sup.2 and R.sup.3 are each hydrogen, lower alkyl, halo(lower)alkyl or acyl,
 R.sup.4 is aryl having suitable substituent(s), or a heterocyclic group optionally having suitable substituent(s),
 Q is O or N--R.sup.11, in which R.sup.11 is hydrogen or acyl, and
 A is lower alkylene,
 and pharmaceutically acceptable salts thereof.
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 9 USPATFULL on STN
 ACCESSION NUMBER: 97:71069 USPATFULL
 TITLE: N-aryl and N-heteroaryl amide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
 INVENTOR(S): Chang, George, Ivoryton, CT, United States
 Hamanaka, Ernest S., Gales Ferry, CT, United States
 McCarthy, Peter A., Pawcatuck, CT, United States
 Truong, Thien V., Old Saybrook, CT, United States
 Walker, Frederick J., Preston, CT, United States
 Pfizer Inc., New York, NY, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5656634		19970812
US 1994-251075		19940531 (8)

PATENT INFORMATION: Division of Ser. No. US 1992-916651, filed on 20 Jul 1992, now patented, Pat. No. US 5362878 which is a continuation-in-part of Ser. No. US 1991-648677, filed on 21 Mar 1991, now abandoned
 RELATED APPLN. INFO.:
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Rotman, Alan L.
 ASSISTANT EXAMINER: Mach, D. Margaret M.
 LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Bekelnitzky, Seymour G.
 NUMBER OF CLAIMS: 7
 EXEMPLARY CLAIM: 1
 LINE COUNT: 3701
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compounds of the formula ##STR1## the pharmaceutically acceptable salts thereof, wherein Q and R.sup.1 are as defined below, and novel carboxylic acid and acid halide intermediates used in the synthesis of such compounds. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 9 USPATFULL on STN
 ACCESSION NUMBER: 96:104005 USPATFULL
 TITLE: Imidazo [1,2-a] pyridines and their pharmaceutical use
 INVENTOR(S): Oku, Teruo, Tsukuba, Japan
 Kayakiri, Hiroshi, Tsukuba, Japan
 Satoh, Shigeki, Tsukuba, Japan
 Abe, Yoshito, Ibaraki, Japan
 Sawada, Yuki, Tsukuba, Japan
 Tanaka, Hirokazu, Takarazuka, Japan
 Fujisawa Pharmaceutical Co., Ltd, Osaka, Japan
 (non-U.S. corporation)

NUMBER	KIND	DATE
US 5574042		19961112
US 1995-441786		19950516 (8)

PATENT INFORMATION: Continuation of Ser. No. US 1994-235632, filed on 29 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-142967, filed on 29 Oct 1993, now abandoned
 RELATED APPLN. INFO.:
 NUMBER DATE
 PRIORITY INFORMATION: GB 1992-22947 19921102
 GB 1993-4249 19930303
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Dentz, Bernard
 LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
 NUMBER OF CLAIMS: 11
 EXEMPLARY CLAIM: 1
 LINE COUNT: 7946
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to novel bradykinin antagonists of the formula: ##STR1## wherein R.sup.1 is halogen,
 R.sup.2 and R.sup.3 are each hydrogen, lower alkyl, halo(lower)alkyl or acyl,
 R.sup.4 is aryl having suitable substituent(s), or a heterocyclic group optionally having suitable substituent(s),
 Q is O or N--R.sup.11, in which R.sup.11 is hydrogen or acyl, and
 A is lower alkylene,
 and pharmaceutically acceptable salts thereof.
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

10/616,579

L5 ANSWER 9 OF 9 USPATFULL on STN

ACCESSION NUMBER: 94:97714 USPATFULL

TITLE: Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)

INVENTOR(S): Chang, George, Ivoryton, CT, United States
Hamanaka, Ernest S., Gales Ferry, CT, United States
McCarthy, Peter A., Pawcatuck, CT, United States
Truong, Thien, Saybrook, CT, United States

PATENT ASSIGNEE(S): Walker, Frederick J., Preston, CT, United States
Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5362878		19941108
APPLICATION INFO.:	US 1992-916651		19920720 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-648677, filed on 21 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Chang, Celia		
LEGAL REPRESENTATIVE:	Richardson, Peter C., Ginsburg, Paul H., Bekeznitzky, Seymour G.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3480		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula ##STR1## wherein R.sup.21 and R.sup.22 are as defined in the specification which are intermediates useful in the preparation of compounds of the formula ##STR2## and the pharmaceutically acceptable salts thereof, wherein Q and R.sup.1 are as defined in the specification. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

10/616,579

=> d his

(FILE 'HOME' ENTERED AT 14:41:04 ON 09 MAR 2005)

FILE 'REGISTRY' ENTERED AT 14:41:08 ON 09 MAR 2005

L1 STRUCTURE UPLOADED

L2 20 S L1 SAM

L3 325 S L1 FULL

FILE 'CA' ENTERED AT 14:41:29 ON 09 MAR 2005

L4 15 S L3

FILE 'USPATFULL' ENTERED AT 14:41:53 ON 09 MAR 2005

L5 9 S L3

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 14:42:25 ON 09 MAR 2005